Back to top
more

American Renal Associates Holdings, Inc (ARA)

(Delayed Data from NYSE)

$7.61 USD

7.61
156,020

+0.41 (5.69%)

Updated May 3, 2019 04:02 PM ET

After-Market: $7.61 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

American Renal Associates (ARA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

American Renal Associates (ARA) delivered earnings and revenue surprises of -214.29% and -0.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

American Renal Associates (ARA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

American Renal Associates (ARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

American Renal Associates (ARA) Catches Eye: Stock Jumps 9.8%

by Zacks Equity Research

American Renal Associates (ARA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

ARA vs. USPH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ARA vs. USPH: Which Stock Is the Better Value Option?

All You Need to Know About American Renal Associates (ARA) Rating Upgrade to Buy

by Zacks Equity Research

American Renal Associates (ARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Can American Renal Associates (ARA) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

American Renal Associates (ARA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ARA vs. USPH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ARA vs. USPH: Which Stock Is the Better Value Option?

American Renal Associates (ARA) Q3 Earnings Beat Estimates

by Zacks Equity Research

American Renal Associates (ARA) delivered earnings and revenue surprises of 46.15% and -2.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate American Renal Associates (ARA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

American Renal Associates (ARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

American Renal Associates (ARA) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

American Renal Associates (ARA) delivered earnings and revenue surprises of 25.00% and 6.62%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    American Renal Associates (ARA) Looks Good: Stock Rises 8%

    by Zacks Equity Research

    American Renal Associates Holdings (ARA) shares rose over 8% in the last trading session.